



# Bulletin #03

## RFSO Questions and Answers

### File #C-234410 Post-Market Drug Evaluation (PMDE)

**CADTH Confidentiality Statement:** This document and all attachments herein are intended solely for the use of the individual(s) and/or organization(s) to which it is directed. It may contain privileged, confidential, or copyright-protected information. By accepting possession of this document, you agree to keep its contents in confidence and to not use, duplicate, or disclose the document to any other party for any purpose other than providing the services herein, unless otherwise agreed to in writing by CADTH.

Any unauthorized use of this document, copying, review, or disclosure, including use by anyone other than the intended recipient, is prohibited. If received in error, please delete this document and all copies immediately from your system and notify the sender promptly by email that you have done so.

**Note by CADTH: Questions may have been edited for clarity or to maintain confidentiality.**

**Question #01 received March 6, 2024**

Reference 2.4.2 Financial Proposal

**Question:** Is there any in-kind contribution requirement?

**Answer:** There is no requirement for in-kind contributions.

End of file.